Medicine composition for ophthalmology department

A composition and ophthalmic technology, applied in the direction of drug combination, boron compound active ingredient, heavy metal active ingredient, etc., can solve the problems of cyclodextrin deposition instability hidden danger, irritation and lack of stability, etc., to ensure chemical stability , easy to accept treatment, long-lasting effect

Active Publication Date: 2005-12-07
SHENYANG XINGQI PHARM CO LTD
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In July 1995, Ruosu Pharmaceutical Co., Ltd. Takeuchi Masashi and others applied for the patent of "anti-inflammatory eye drops" with the authorization notification number CN 1087169C. It uses diclofenac sodium as the main drug in a wide range of concentrations. Diclofenac sodium, A patent for an invention made by using γ-cyclodextrin (γ-CyD), polyvinylpyrrolidone (PVP) in combination with benzethonium chloride or benzalkonium chloride as a preservative and adjusting the pH to 7.0-8.5 , its purpose is to reduce the irritation and strong eye pain effect of eye drops, but the disadvantage of this invention is that it uses strong acid and strong base to adjust the ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] The following ophthalmic pharmaceutical compositions were prepared in the following proportions.

[0024] Diclofenac Sodium 1.0g

[0025] Borax 3.0g

[0026] Boric acid 1.5g

[0027] Tromethamine 2.0g

[0028] Sodium chloride 7.1g

[0029] Add water for injection to 1000.0ml

[0030] Preparation Process

[0031] Take about 50% of the prescribed amount of water for injection, dissolve diclofenac sodium, add borax, boric acid, tromethamine, and sodium chloride in turn after fully dissolved, heat to 100°C and boil for 15 minutes, cool down, and make up the full amount with water for injection.

Embodiment 2

[0033] prescription:

[0034] Diclofenac Sodium 0.5g

[0035] Borax 3.0g

[0036] Boric acid 1.5g

[0037] Sodium Hyaluronate 1.0g

[0038] Thimerosal 0.04g

[0039] Tromethamine 0.3g

[0040] Sodium chloride 6.3g

[0041] Add water for injection to 1000.0ml

[0042]Take the prescribed amount of sodium hyaluronate, add an appropriate amount of water for injection, and prepare a 0.1% solution, place it at 2-10°C for more than 12 hours, and set aside; take about 50% of the prescribed amount of water for injection, dissolve diclofenac sodium, and dissolve it completely Add borax, boric acid, tromethamine and sodium chloride in sequence, heat to 100°C and boil for 15 minutes, cool down to 35-40°C, add sodium hyaluronate solution, add thimerosal dissolved in advance, make up to full amount with water for injection, that is Obtain the composition of the present invention, its pH value is 8.2.

Embodiment 3

[0044] prescription:

[0045] Diclofenac Sodium 2.0g

[0046] Borax 11.5g

[0047] Boric acid 4.5g

[0048] Sodium Hyaluronate 0.2g

[0049] Thimerosal 0.04g

[0050] Tromethamine 1.2g

[0051] Sodium chloride 3.0g

[0052] Add water for injection to 1000.0ml

[0053] According to above-mentioned prescription, operate with the same method of embodiment 2, promptly obtain composition of the present invention, its pH value is 8.8.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a medicinal composition for ophthalmology department which comprises diclofenac sodium 0.05-0.2%, trometamol 0.02-0.2%, borax 0.3-3.0%, boracic acid 0.1-1.0%, sodium hyaluionate 0.01-0.1%, thiomersal 0.001-0.01%, the component ratio being weight / volume percentage, the pH of the composition aqueous solution is 6.5-9.0.

Description

[technical field] [0001] The invention relates to an anti-inflammation ophthalmic pharmaceutical composition for topical use on the eye with diclofenac sodium as an active ingredient. The composition has good drug stability and less irritation. [Background technique] [0002] Diclofenac and its salts are non-steroidal anti-inflammatory analgesics derived from phenylacetic acid, used as a substitute for corticosteroids for the treatment of eye diseases. Side effects from corticosteroids, as well as some adverse effects and increased intraocular pressure. Because of its strong blocking effect on the biosynthesis of prostaglandins, it is used to prevent postoperative inflammation and postoperative complications during cataract surgery; when diclofenac and its salts are used in the eye, almost without exception Stimulate mucous membranes and eyes and show strong eye pain; at the same time, there are also changes in the appearance and internal quality of the preparations to vary...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K33/22
Inventor 刘继东
Owner SHENYANG XINGQI PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap